Results 141 to 150 of about 6,754 (182)

Neuronal CD59 isoforms IRIS-1 and IRIS-2 as regulators of neurotransmitter release with implications for Alzheimer's disease. [PDF]

Alzheimers Res Ther
Golec E, Olsson R, Tuysuz EC, Karlsson M, Serjieh Y, King BC, Wennström M, Blom AM.   +7 more
europepmc   +1 more source

Simultaneous high throughput genotyping of 36 blood group systems using NGS based on probe capture technology. [PDF]

Heliyon
Zhang J, Yuan W, Hong X, Ying Y, Zhu F.
europepmc   +1 more source

Plasma Glycated CD59 and Gestational Diabetes Mellitus: A Systematic Review. [PDF]

Endocrinol Diabetes Metab
Asadi Z, Safari-Faramani R, Aghaz F, Vaisi-Raygani A, Jalilian S.   +4 more
europepmc   +1 more source

Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression. [PDF]

Front Immunol
Nguyen OTP, Lara S, Ferro G, Peipp M, Kleinau S.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The CD59 antigen is a structural homologue of murine Ly‐6 antigens but lacks interferon inducibility

European Journal of Immunology, 1990
AbstractA cDNA encoding the human leukocyte antigen CD59 has been isolated from the erythroid cell line K‐562 and its identity confirmed through expression in COS cells. Northern blotting reveals three message species of approximately 800, 1400 and 2000 bases in size, which are constitutively expressed in all lymphoid, erythroid, myeloid, and neural ...
W M, Philbrick, R G, Palfree, S E, Maher, M M, Bridgett, S, Sirlin, A L, Bothwell   +5 more
openaire   +2 more sources

Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation

Journal of Leukocyte Biology, 1992
Abstract Expression of decay-accelerating factor (DAF or CD55) and of CD59 during hematopoietic cell development in normal bone marrow and on peripheral blood leukocytes were characterized by three-color immunofluorescence experiments.
L W, Terstappen, M, Nguyen, H M, Lazarus, M E, Medof   +3 more
openaire   +2 more sources

Glycated-CD59 antigen: exploration of synthetic approaches

2009
S. Cantel, A. Kavishwar, M. Schlimme, A. Khatri, J.A. Halperin and M. Chorev Laboratory for Translational Research, Harvard Medical School, One Kendall Square, Building 600, Cambridge MA 02391 and Brigham and Women’s Hospital, Department of Medicine, 75 Francis Street, Boston, MA 02115, USA; IBMM, Max Mousseron Institute of Biomolecules, CNRS UMR 5247,
S, Cantel, A, Kavishwar, M, Schlimme, A, Khatri, J A, Halperin, M, Chorev   +5 more
openaire   +2 more sources

Isolation and Expression of the Full-Length cDNA Encoding CD59 Antigen of Human Lymphocytes

DNA and Cell Biology, 1990
To identify the primary structure of CD59 antigen and to elucidate its function, a full-length cDNA clone of CD59 was isolated. The cDNA sequence contained an open reading frame that encodes an 128-amino-acid peptide. The amino-terminal 25 amino acids represented a typical signal peptide sequence and the carboxy-terminal hydrophobic amino acids were ...
R, Sawada, K, Ohashi, H, Anaguchi, H, Okazaki, M, Hattori, N, Minato, M, Naruto   +6 more
openaire   +2 more sources

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer

Journal of Gastrointestinal Surgery, 2001
Despite radical surgery, the prognosis for colorectal cancer patients with liver metastases has not changed markedly. Furthermore, no standard adjuvant therapeutic regimen has been developed. Adjuvant therapy with monoclonal antibodies (e.g., against 17-1A), which has been shown to be effective in preventing metastatic relapse in patients with Dukes' C
S B, Hosch, P, Scheunemann, M, Lüth, S, Inndorf, N H, Stoecklein, A, Erbersdobler, A, Rehders, M, Gundlach, W T, Knoefel, J R, Izbicki   +9 more
openaire   +2 more sources